Compare WKEY & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | CYPH |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 73.3M |
| IPO Year | 2019 | 2019 |
| Metric | WKEY | CYPH |
|---|---|---|
| Price | $5.66 | $2.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.7K | ★ 15.9M |
| Earning Date | 09-30-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 103.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,500,000.00 |
| Revenue This Year | $64.54 | N/A |
| Revenue Next Year | $52.80 | $408.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.32 | $0.49 |
| 52 Week High | $19.80 | $4.19 |
| Indicator | WKEY | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 55.23 |
| Support Level | $5.74 | $0.68 |
| Resistance Level | $6.94 | $3.23 |
| Average True Range (ATR) | 0.29 | 0.48 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 36.23 | 50.35 |
WISeKey International Holding Ltd at the forefront of authentication and cybersecurity technology. It develops, markets, hosts, and supports a range of solutions that enable the secure digital identification and communication of people, content, and objects, by generating digital identities that enable its clients to monetize their existing user bases and, at the same time, expand their own eco-system securely by ensuring only authenticated objects and people can connect. The WISeKey Group operates through five core verticals: SEALSQ, WISeSat, SEALCOIN, WISeID, & WISe.ART. It has two business segments. Semiconductors & ASICs. The majority of its revenue is generated from the Semiconductors segment.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.